IDEXX (IDXX) Jumps 22% on Q3 Beat, but the Margin Outlook Slipped

IDEXX Laboratories (IDXX) had a very good Monday. The veterinary diagnostics company beat third-quarter estimates, raised its 2026 forecast, and closed up 21.85% at $671.64.

That's a market value of about $52.9 billion, though the stock is still below its 52-week high of $769.98. CNBC noted midday that it topped both revenue and earnings expectations, driven by growth in its Companion Animal Group.

For anyone new to the name, IDEXX sells diagnostic tests, analyzers and software to veterinary clinics. Most of its revenue recurs, because clinics keep buying the supplies and tests that run on its equipment.

The numbers were solid. Revenue rose 10% to about $1.21 billion from $1.11 billion a year earlier, and diluted earnings per share climbed 18% to $4.01 from $3.40.

Recurring diagnostics revenue from vets, the steady core of the business, reached $967 million, up 11%. Operating margin improved to 33.1% from 32.1%.

The engine under the hood is the razor-and-blade model. VetLab consumables, the supplies vets use on IDEXX's in-clinic analyzers, rose 14% and made up more than half of the recurring gain, as The Motley Fool's analysis laid out.

That also explains why flat instrument revenue isn't a worry. Each new analyzer placed in a clinic keeps generating test sales for years, so placements matter more than the price of the box.

This is the detail the headline skipped. IDEXX raised its revenue range but trimmed its operating margin outlook, which leaves full-year operating profit about where the old midpoint had it.

The $0.25 lift to the EPS forecast leans instead on a lower tax rate, less interest expense, and fewer shares.

In other words, the earnings raise didn't come from selling more tests. Lower taxes, cheaper interest and buybacks help this year, but they don't compound the way test volume does.

The margin cut also points straight at the fourth quarter. Margin gains through nine months already top the new full-year target, which implies little or no improvement in the last three months.

Put simply, the business is spending more to improve how clinics work, and that spending eats into profit before it shows up in sales. Whether it pays off depends on how many clinics adopt the software.

Management is absorbing costs from its CoVet software deal, and that is where the margin pressure shows up. It's an investment in the clinic workflow, but investors are paying for it now.

There is another soft spot. Rapid assay testing volumes fell this quarter, and price alone kept sales in that category growing.

Price-led growth can only run so long before vets push back. If volumes in that line keep sliding, the strength in consumables will have to carry the load.

Even after the jump, the stock hasn't fully recovered its highs. The 52-week low is $500.61, so Monday's close sits well above the bottom of the range but still about 13% under the top.

After a 22% one-day pop, the question is what's left in the tank. The core business is healthy and the razor-and-blade model is working, but the stock now prices in a lot of that.

For current holders, nothing in the report argues for selling a franchise this durable. For new money, waiting for the first week of excitement to cool may offer a better price than buying a gap-up.

Watch the fourth-quarter operating margin against last year's, since guidance implies it barely moves. Also track rapid assay volumes and early traction from CoVet.

Bottom line: IDEXX's testing engine is humming, but this raise was built on financial engineering, so the next quarter has to prove the margins.